Lyrica® (pregabalin) – First-time generic

- On July 23, 2019, Ascend Laboratories launched an AA-rated generic version of Pfizer’s Lyrica (pregabalin) oral solution.

- Lyrica is indicated for:
  - Management of neuropathic pain associated with diabetic peripheral neuropathy
  - Management of postherpetic neuralgia
  - Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
  - Management of fibromyalgia
  - Management of neuropathic pain associated with spinal cord injury

- Pregabalin is also available as a generic capsule and branded extended-release tablet (Lyrica CR).
  - The oral capsule carries the same indications as the oral solution.
  - Lyrica CR is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.